2026 Peptide Policy Timeline: FDA, OIRA, and HHS Dates

The FDA meeting page documents the Pharmacy Compounding Advisory Committee’s July 23–24, 2026 meeting. The agenda covered BPC-157, KPV, TB-500, and MOTS-c-related bulk substances on the first day, followed by emideltide, Semax, and Epitalon-related substances on the second.

The page also explains that advisory recommendations are nonbinding. That makes the July meeting an important input, not a date when seven medicines received FDA approval. The agenda names uses evaluated for the compounding discussion. It does not turn those uses into approved indications or extend the eventual policy to every chemical form considered in July.

The official OIRA record gives October 14, 2026 as the received date for “Interim Access Policy for Compounding Using Certain Peptides.” It identifies HHS/FDA, the notice stage, and RIN 0910-ZD94. This is the verifiable basis for coverage describing submission for White House regulatory review.

Receipt means the policy entered that review process. It should not be described as publication, clinical approval, or an access guarantee. Older reports written during this period may accurately describe the proposal as pending at that time. Their status language needs a date when used alongside later developments.

The same OIRA entry lists October 27 as the concluded date and “Consistent with Change” as the outcome. This supports saying the review concluded before HHS made the notice public on October 28. It does not reveal every revision or establish which participant requested a particular change.

The title of the review record also differs from the title of the later HHS notice. Matching the RIN helps connect them without assuming that a headline or abbreviated title contains the full policy terms. Our OIRA explainer describes what this administrative milestone can and cannot establish.

The public-inspection notice announces availability of a draft enforcement-discretion policy and is signed by HHS Secretary Robert F. Kennedy Jr. It links the HHS policy and appendices, which specify the six substances and conditions. The notice calls the approach interim and says it is nonbinding.

It also explicitly states that compounded drugs are not FDA-approved. That sentence is essential to reading the date correctly: October 28 marks the public announcement of this policy, not approval of six medicines. The notice says HHS may revisit the policy for safety or quality concerns, and describes possible future rulemaking on the bulks list.

As of this article’s October 28 update, the notice says Federal Register publication is scheduled for October 30, 2026. It allows written comments until two weeks after publication. Readers should confirm the published notice and docket before relying on a calendar deadline, because a scheduled publication is not a completed event.

The retrieved documents do not justify inventing a separate effective date or promising that a pharmacy can begin supplying a product on a particular day. Future rulemaking, later policy updates, and clinical evidence remain distinct developments to track. If you save this timeline, also save the source links: later changes may matter more than the original headline. The public-comment guide explains how to follow the docket without treating it as a route to personal medical advice.